Floatz logo

Molgramostim

Malignant Ascites

Second Affiliated Hospital of Soochow Universityprotein_peptidePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Malignant Ascites cohort.

Asset / SponsorPhaseRating
Catumaxomab
Neovii Biotech
Phase 2/3BB
5,5'-DINITROSALICIL
Wuhan YZY Biopharma Co., Ltd.
Phase 3BB
Metformin
University of Chicago
Phase 2B
Serplulimab
Second Affiliated Hospital of Soochow University
Phase 1/2CC
PD-L1 CAR-T cells
Sichuan University
Phase 1CC

View all 14 →

Same molecule, other indications

Molgramostim is also rated in:

cystic fibrosisDormant
CCC
Indicative ·
55 / 100
View asset →
cutaneous melanomaDormant
CCC
Indicative ·
55 / 100
View asset →
Mycobacterium Infections, NontuberculousDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →